Lexeo Therapeutics Inc
For the period ended Dec 31, 2023. Filed Mar 11, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 11, 2024
LXEO$3.14+8.7%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets
(In thousands, except share and per share amounts)
| December 31, | December 31, | |
|---|---|---|
| 2023 | 2022 | |
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $121,466 | $77,335 |
| Prepaid expenses | 2,825 | 2,342 |
| Other current assets | 3 | 371 |
| Total current assets | 124,294 | 80,048 |
| Restricted cash | 3,252 | 3,253 |
| Property and equipment, net | 1,056 | 998 |
| Lease right-of-use assets - finance, net | 1,763 | 2,069 |
| Lease right-of-use assets - operating | 9,442 | 10,708 |
| Total assets | $139,807 | $97,076 |
| Liabilities, Convertible Preferred Stock and Stockholders' Equity (Deficit) | ||
| Current liabilities: | ||
| Accounts payable | $3,794 | $2,678 |
| Taxes payable | 157 | 506 |
| Accrued expenses and other current liabilities | 7,873 | 6,420 |
| Accrued bonuses | 2,810 | 1,911 |
| Current portion of lease liabilities - finance | 518 | 547 |
| Current portion of lease liabilities - operating | 2,087 | 2,287 |
| Total current liabilities | 17,239 | 14,349 |
| Non-current liabilities | ||
| Non-current portion of lease liabilities - finance | 1,247 | 1,648 |
| Non-current portion of lease liabilities - operating | 7,786 | 9,000 |
| Total liabilities | 26,272 | 24,997 |
| Commitments and contingencies (Note 12) | ||
| Series A convertible preferred stock, no par value; no shares authorized, issued, and outstanding as of December 31, 2023; $0.0001 par value; 85,495,722 shares authorized, issued, and outstanding as of December 31, 2022; aggregate liquidation value of $85,496 as of December 31, 2022 | — | 85,268 |
| Series B convertible preferred stock, no par value; no shares authorized, issued, and outstanding as of December 31, 2023; $0.0001 par value; 58,157,824 shares authorized as of December 31, 2022; 58,157,823 shares issued and outstanding as of December 31, 2022; aggregate liquidation value of $100,060 as of December 31, 2022 | — | 99,765 |
| Stockholders' equity (deficit): | ||
| Common stock, $0.0001 par value, 500,000,000 shares authorized as of December 31, 2023; 26,668,485 shares issued and 26,646,378 shares outstanding as of December 31, 2023; 18,125,051 shares authorized as of December 31, 2022; 1,648,734 shares issued and 1,607,185 shares outstanding as of December 31, 2022 | 3 | — |
| Additional paid-in capital | 295,372 | 2,492 |
| Accumulated deficit | (181,840) | (115,446) |
| Total stockholders' equity (deficit) | 113,535 | (112,954) |
| Total liabilities, preferred stock and stockholders' equity (deficit) | $139,807 | $97,076 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.